KVX 053
Alternative Names: JMS-053; JMS-631-053; KVX-053Latest Information Update: 02 Jun 2022
At a glance
- Originator University of Pittsburgh; University of Virginia
- Developer KeViRx
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action PTP4A3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Cancer; Ovarian cancer; Respiratory tract disorders
Most Recent Events
- 23 May 2022 Preclinical trials in Cancer in USA (Parenteral) Before May 2022 (KeViRx pipeline, May 2022)
- 23 May 2022 KVX 053 is available for licensing as of 23 May 2022. http://www.kevirx.com/opportunities
- 08 Apr 2022 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) before May 2022 (KeViRx pipeline, May 2022)